Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Martin

Showing results (301-310 of 315) with videos related to

Pageof 32
Sort By:
Annals of the Rheumatic Diseases|April 27, 2018
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)Pierre Charles, Benjamin Terrier, Élodie Perrodeau, et al.
Global Change Biology|September 10, 2025
Multiyear Drought Strengthens Positive and Negative Functional Diversity Effects on Tree Growth ResponseHernán Serrano-León, Haben Blondeel, Paula Glenz, et al.
Rheumatology (Oxford, England)|May 25, 2020
Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysisPierre Charles, Agnès Dechartres, Benjamin Terrier, et al.
Global Change Biology|September 24, 2024
Tree drought-mortality risk depends more on intrinsic species resistance than on stand species diversityRenaud Decarsin, Joannès Guillemot, Guerric le Maire, et al.
Annals of Internal Medicine|June 2, 2020
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized TrialPierre Charles, Élodie Perrodeau, Maxime Samson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 17, 2015
Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two PatientsEtienne Crickx, Irène Machelart, Estibaliz Lazaro, et al.
British Dental Journal|June 14, 2024
Sustainable oral healthcare: what is it and how do we achieve it?Laura Beaton, Jim Boyle, Heather Cassie, et al.
Plos One|March 23, 2016
Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with CyclophosphamideAlexandra Audemard-Verger, Nicolas Martin Silva, Céline Verstuyft, et al.
Annals of the Rheumatic Diseases|November 2, 2023
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trialsFlorence Delestre, Pierre Charles, Alexandre Karras, et al.
Annals of Internal Medicine|July 28, 2025
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled TrialBenjamin Terrier, Grégory Pugnet, Claire de Moreuil, et al.
Pageof 32

Showing results (301-310 of 315) with videos related to

Sort By:
Pageof 32
Annals of the Rheumatic Diseases|April 27, 2018
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)Pierre Charles, Benjamin Terrier, Élodie Perrodeau, et al.
Global Change Biology|September 10, 2025
Multiyear Drought Strengthens Positive and Negative Functional Diversity Effects on Tree Growth ResponseHernán Serrano-León, Haben Blondeel, Paula Glenz, et al.
Rheumatology (Oxford, England)|May 25, 2020
Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysisPierre Charles, Agnès Dechartres, Benjamin Terrier, et al.
Global Change Biology|September 24, 2024
Tree drought-mortality risk depends more on intrinsic species resistance than on stand species diversityRenaud Decarsin, Joannès Guillemot, Guerric le Maire, et al.
Annals of Internal Medicine|June 2, 2020
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized TrialPierre Charles, Élodie Perrodeau, Maxime Samson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 17, 2015
Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two PatientsEtienne Crickx, Irène Machelart, Estibaliz Lazaro, et al.
British Dental Journal|June 14, 2024
Sustainable oral healthcare: what is it and how do we achieve it?Laura Beaton, Jim Boyle, Heather Cassie, et al.
Plos One|March 23, 2016
Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with CyclophosphamideAlexandra Audemard-Verger, Nicolas Martin Silva, Céline Verstuyft, et al.
Annals of the Rheumatic Diseases|November 2, 2023
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trialsFlorence Delestre, Pierre Charles, Alexandre Karras, et al.
Annals of Internal Medicine|July 28, 2025
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled TrialBenjamin Terrier, Grégory Pugnet, Claire de Moreuil, et al.
Pageof 32